作者
Mutlu Hızal,Burak Bi̇lgi̇n,Nail Paksoy,Saadettin Kılıçkap,Muhammed Mustafa Atçı,Seda Kahraman,Merve Keskinkılıç,İrem Bilgetekin,Murat Ayhan,Deniz Tural,Orhan Önder Eren,Fatma Nihan Akkoç Mustafayev,Şebnem Yaman,Ali Murat Tatlı,Ertuğrul Bayram,Yasin Kutlu,İsmail Ertürk,Erkan Özcan,Ahmet Gülmez,Mustafa Korkmaz,Baran Akagündüz,Dilek Erdem,Tuğba Akın Telli,Asude Aksoy,Necdet Üskent,Yakup İriağaç,Naziyet Köse Baytemür,Dinçer Aydın,Teoman Şakalar,Hacı Arak,Fatih Selçukbiricik,Yakup Ergün,Taner Korkmaz,Naziye Ak,Çağlar Ünal,Nadiye Akdeniz,Mehmet Alpaslan Özgün,Berna Öksüzoğlu,Bülent Yalçın,İlhan Öztop,Efnan Algın,Abdullah Sakin,Adnan Aydıner,Perran Fulden Yumuk,Mehmet Alı Nahıt Şendur
摘要
Aims: In this multicenter study, the authors aimed to determine the real-life efficacy and safety of first-line alectinib. Materials & methods: This retrospective trial included advanced-stage, ALK-positive non-small-cell lung cancer patients who were treated with first-line alectinib in terms of ALK-tyrosine kinase inhibitors, regardless of previous chemotherapy. The co-primary end points were progression-free survival both for all patients and for the treatment-naive population. The secondary end points were overall response rate, overall survival, rate of CNS progression and safety. Results & conclusion: A total of 274 patients (n = 177 for treatment-naive patients) were enrolled in the study. The median progression-free survival was 26 and 28.8 months for all patients and the treatment-naive group, respectively. The overall response rate, CNS progression rate and 1-year overall survival ratio were 77.9, 12.4 and 77%. Alectinib is a highly effective therapy with a favorable safety profile.